Jefferson Health Plans

2024 PRIOR AUTHORIZATION REQUEST FORM

Individual and Family Plans

Xeljanz

Fax back to: (833) 605-4407

Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**
Member Number:	Fax: Phone:
Date of Birth:	Office Contact:
Line of Business: □ Exchange - PA	NPI: State Lic ID:
Address:	Address:
City, State ZIP:	City, State ZIP:
Primary Phone:	**Specialty/facility name (if applicable):**

☐ REQUEST FOR EXPEDITED REVIEW: By checking this box and signing below, I certify that the standard review timeframe may seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function.

Drug Name:	
Strength:	
Directions / SIG:	

Please attach any pertinent medical history including labs and information for this member that may support approval.
Please answer the following questions and sign.

Q1. Is this a reauthorization request?

☐ Yes - Go to 2 ☐ No - Go to 3

Q2. Is there confirmation of continued positive clinical response since starting Does Xeljanz/Xeljanz XR?

☐ Yes ☐ No

Q3. Is the requested drug being prescribed by or in consultation with a rheumatologist, dermatologist, or gastroenterologist?

☐ Yes ☐ No

Q4. Does the patient have the diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) or active polyarticular course juvenile idiopathic arthritis (PJIA)?

☐ Yes ☐ No

Jefferson Health Plans

2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Xeljanz

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**

Q5. Is there documentation of an inadequate response, intolerance, or contraindication to at least one TNF blocker for RA, PsA and AS, or to at least one first-line therapy (including full-dose NSAIDs) for PJIA?

☐ Yes ☐ No

Q6. Does the patient have the diagnosis of ulcerative colitis (UC)?

☐ Yes ☐ No

Q7. Is there documentation of an inadequate response, intolerance, or contraindication to at least one treatments (such as one of the following: tumor necrosis factor antagonist, oral or intravenous corticosteroid, azathioprine or 6-MP)?

☐ Yes ☐ No

Q8. Is the patient 18 years of age or older for RA, PsA, AS or UC, or 2 years of age or older for PJIA?

☐ Yes ☐ No

Q9. Has the patient been evaluated for current infections including active or latent tuberculosis (TB) infection with a tuberculin skin test prior to the initiation of therapy?

☐ Yes ☐ No

Q10. Was the tuberculin skin test negative?

☐ Yes ☐ No

Q11. Is there a treatment plan for the active or latent infection?

☐ Yes ☐ No

Q12. Will the requested drug be used concomitantly with other biologic disease modifying anti-rheumatic drugs (DMARDs) or potent immunosuppressants (such as azathioprine or cyclosporine)?

Jefferson Health Plans

2024 PRIOR AUTHORIZATION REQUEST FORM
Individual and Family Plans

Xeljanz

Fax back to: (833) 605-4407
Phone: (215) 991-4300

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	**Prescriber Name:**
☐ Yes	☐ No
Q13. Additional Information:	

Prescriber Signature

Date

2024 Prior Authorization Request